EndoChoice® Launches Third Generation Fuse® Full Spectrum Endoscopy® SystemBack
ALPHARETTA, Ga., May 19, 2016 /PRNewswire/ — EndoChoice Holdings, Inc. (NYSE: GI) announced today the full market release of its Generation 3 Full Spectrum Endoscopy® (Fuse®) system. Fuse Generation 3 includes an ergonomically advanced control body, incorporating over 50 system enhancements and a novel Adaptive Matrix Imaging technology called Lumos™, that enables physicians to see more with enhanced clarity. The company is beginning sales and distribution of Generation 3 scopes in the United States, European Union, and other select markets.
Lumos Adaptive Matrix Imaging takes a revolutionary approach to enhance the view of the mucosal structures and vascular patterns in their natural color and the ability for “always-on” functionality via smart enhancement technology, making it the first advanced imaging solution designed to improve the entire procedure. Lumos is now launched in Europe with the CE mark, and is pending FDA clearance in the United States.
EndoChoice will highlight Fuse Generation 3 at Digestive Disease Week® (DDW®) in San Diego, California (Booth #4317), and at the SGNA™ 43rd Annual Course in Seattle, Washington. EndoChoice will display at these meetings May 22 to 24.
Commenting on the new product release, Dr. Booker Dalton, Gastroenterologist at Digestive Healthcare of Georgia, said “Fuse Generation 3 is a significant advancement of the Full Spectrum Endoscopy system. Fuse’s new ergonomic design and system refinements greatly enhance the overall user experience. Coupled with its already impressive 330-degree field of view and published clinical value, Fuse is a game changer.”
Mark Gilreath, Founder and CEO of EndoChoice, stated, “We are truly excited to bring Fuse Generation 3 and Lumos to the world of GI. With Generation 3, not only do GI’s have an increased field of view to help detect lesions, they now have the ability to enhance anatomy like never before with Lumos Adaptive Matrix Imaging. We believe these advancements take the Fuse platform to an unprecedented level in endoscopic screening.”
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW take place May 21-24, 2016, at the San Diego Convention Center, San Diego, CA. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org
The Society of Gastroenterology Nurses and Associates, Inc. (SGNA™) 43rd Annual Course in Seattle is the premier education and networking event dedicated to gastroenterology and endoscopy nursing professionals. The event will take place May 22-24, 2016 in Seattle, Washington. More information can be found at www.sgna.org/2016annualcourse
Based near Atlanta, Georgia, EndoChoice® (NYSE: GI) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries. The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy® (Fuse®) system. EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.